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ABSTRACT
The introduction of silver nitrate for prophylaxis ofgonoc0ccal ophthalmia neonatorum is one ofthe
milestones of preventive medicine. However, in our time an increasing necessity to review Credf’s
prophylaxis from both a human rights and a medical standpoint is required. The chairmen of the
obstetrics and gynecology departments of the German university hospitals were questioned to learn
about their policy and experience. Data were provided by 22 of 28 consulted institutions, represent-
ing 31,700 annual deliveries seen over a mean period of 5.5 years. Ocular prophylaxis was in use in
16 (73%) of the reporting hospitals (1% silver nitrate in 14 and gentamicin in 2). A nonspecific
conjunctival reaction occurred in 5-10% of the newborns, but no major side effects were seen.
Non-gonococcal ophthalmia neonatorum was observed in less than 0.1%; however, institutions
without a preventive policy reported up to a 5% incidence of neonatal conjunctivitis, mostly due to
Staphylococcus aureus, as well as Neisseria gonorrhoeae in two newborns. Application of silver nitrate
is considered a necessary prophylactic measure and safe if it is properly administered. However,
major efforts should be directed toward its replacement by alternative antiseptic substances as well
as toward chlamydial screening and therapy in pregnancy. (C) 1993 Wiley-Liss, Inc.
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he establishment of silver nitrate prophylaxis of
gonococcal ophthalmia neonatorum is one of
the milestones of preventive medicine in the 19th
century. In 1881 Carl Siegmund Franz CredO, one
of the first editors and founder of the famous jour-
nal Archivfiir Gyn#kologie, reported from Leipzig
a decrease in the incidence of gonococcal oph-
thalmia from 7.6% to 0.5% (Table 1) by the use of
2% silver nitrate. In the following years prophy-
laxis was established and required by law or by
health department regulations in many countries all
over the world. In Germany enforcement was ter-
minated in 1986 by the proclamation of a new law
(Gesetz tiber den Beruf der Hebamme und des
Entbindungspflegers vom 4.6. 1986). As a result,
an increasing necessity arose to review Cred’s pro-
phylaxis from both a human rights and a medical
standpoint in the medical profession as well as in
the government.
This paper reports on recent prevention efforts
in German university hospitals on the basis of a
questionnaire. In addition, the literature is evalu-
ated in an attempt to define the current standard of
care according to the position of the German Fed-
eral Health Department (Bundesgesundheitsamt)
at Berlin.
SUBJECTS AND METHODS
In January 1992, 28 chairmen of the departments
of obstetrics and gynecology at the university hospi-
tals in the former West Germany were sent the
following questionnaire concerning prevention of
ophthalmia neonatorum by Cred’s procedure in
their hospitals:
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TABLE I. Incidence of ophthalmia neonatorum in
Cred’s original series before and after initiation of
prophylaxis with 2% silver nitrate
Deliveries Ophthalmia neonatorum
Year (no.) (no.) (%)
1874 323 45 13.6
1875 287 37 12.9
1876 367 29 9.1
1877 360 30 8.3
1878 353 35 9.8
1879 389 36 9.2
1880 (to 5/3 I) 187 14 7.6
1880 (6/I-I 2/8) 200 0.5
aProphylaxis was not administered in this infant.
1. Do you perform neonatal ocular prophylaxis
at your institution? If yes, by what method?
2. Did you observe significant or continuous
adverse reactions following this prophylaxis?
3. Are you aware of any case of gonococcal con-
junctivitis or of conjunctivitis of other etiol-
ogy at your hospital?
4. How many deliveries and how many years
do the figures include?
5. Do you agree to publication of the informa-
tion provided concerning your hospital or do
you prefer anonymity?
6. Do you want to be informed about the results
and the progress of this inquiry?
The last question refers in part to a similar in-
quiry in the university and other major hospitals in
the former East Germany. It was initiated by B.
Viehweg at the same time and presented in April
1992.
All data returned are analyzed and presented
here, in some cases after a precise check-back with
the providing institution. The data obtained were
also taken into consideration in the decision-making
process of the German Federal Health Depart-
ment.
RESULTS
The data requested were provided by 22 of the 28
chairmen between January and March 1992.
However, since three ofthem prefered anonymity,
the participating institutions are listed by numbers
(Table 2). The results reported represent a total of
31,700 annual deliveries seen over a mean period
of 5.5 years (Table 3).
Neonatal ocular prophylaxis was provided in 16
of 22 hospitals (73 %). The use of 1% silver nitrate
was mandatory in 12 hospitals. Occasional applica-
tion because of certain indications or at parents’
requests was reported by one institution each. Two
hospitals performed prophylaxis with gentamicin,
one on request and one as a routine procedure.
Ophthalmia neonatorum but no gonococcal dis-
ease was observed by those hospitals with prophy-
laxis in less than 0.1%. On the other hand, institu-
tions without routine preventive policy or with no
prophylaxis reported up to 5% prevalence of neona-
tal conjunctivitis in general as well as two newborns
with Neisseria gonorrhoeae. Staphylococcus aureus
was specified as the major etiologic pathogen by
some reporters, and in spite of all diagnostic efforts
in the past, chlamydial infection was also demon-
strated at four locations irrespective of prophylaxis
policy.
Nonspecific conjunctival reaction was reported
by 6 of those 12 institutions using 1% silver nitrate
routinely, with an estimated peak incidence of
5-10% on day 2. The other six hospitals did not
observe this kind of reaction; however, it was also
reported by one using gentamicin. Major, long-
lasting, or permanent side effects were denied by
all corresponding institutions, but discontinuation
of prophylaxis was justified by one of them because
of the severity of transient reactions. According to
Viehwegs inquiry in the former East Germany,
silver nitrate was used routinely in 19 of 23 re-
sponding hospitals with no reported major side ef-
fects or long-lasting damage in 860,300 cases.
DISCUSSION
Ophthalmia neonatorum is defined as the occur-
rence of conjunctivitis within the first month of
life. N. gonorrhoeae causes the most destructive
form,
1-5 but other bacterial agents including
Chlamydia trachomatis, Staphylococcus aureus, Strep-
tococcus ssp., Haemophilus spp., and Pseudomonas
spp. can also cause neonatal conjunctivitis3’4’6-9
(Table 4). In general, the incidence of severe oph-
thalmia nenatorum parallels that of maternal gon-
orrhea and chlamydial infection; however, other
pathogens may also lead to conjunctivitis, with re-
sulting septicemia, nasolacrimal duct obstruction,
ulceration, scarring, and blindness in the new-
born.
4 This is in part due to the lack of sufficient
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TABLE 2. Prophylaxis of ophthalmia neonatorum at German university hospitals: Results of an inquiry in January
1992 [response rate 79% (22/28)]
Institution Deliveries/ Observation
no. Method Side effects Ophthalmia year period (years)
Cred None None 800 12
2 Cred 5% None 1,500 10
3 Cred Frequent, at day 2 O. I% C. trachomatis
4 Cred None None 1,000
5 Cred None None 1,800 5
6 Cred 10% C. trachomatis 800 5
7 Cred Frequent 0.1% S. aureus 1,200 5
8 Cred None None 1,600 3
9 Cred None None 1,000
0 Cred None None 2,000
Cred Unspecific Unspecific I, 100 13
12 Cred Unspecific None 500 5
13 Cred None C. trachomatis, some S. aureus 1,000 2
14 Cred None None 1,600 4
15 Gentamicin Unspecific 0.05% 1,800
16 Gentamicin None Rare 1,900
17 None (Unspecific) 2 N. gonorrhoeae, others 2,400 10
18 None 3-5% S. aureus 1,600 S
19 None (Significant) None 1,700 8
20 None (Unspecific)d None 1,600
21 None (Unspecific) Some C. trachornatis, S. aureus 1,000 3
22 None (Unspecific)
d Unspecific 2,400 6
aNo gonococcal infection.
bprophylaxis administered occasionally.
cProphylaxis on parents request.
dBefore prophylaxis was abandoned.
amounts of lysozyme, IgA, and lacrimal fluid on
the newborn cornea.
3
First introduced as prophylaxis against gonococ-
cal ophthalmia neonatorum by Carl Siegmund
Franz Cred in 1880, silver nitrate remained the
standard of care in many countries worldwide; it is
or has been required or recommended by state laws
or health department regulations or officials. 12’13
In addition, it is listed by the World Health Orga-
nization as one of the essential drugs.
14 The current
discussion focusses on some of the problems with
silver nitrate2’15: 1) it does not provide perfect
protection against neonatal (gonococcal) oph-
thalmia; 2) it often causes chemical irritation of the
conjunctiva; and 3) its use may be superfluous in
some populations. To consider these issues a com-
mittee of the German Federal Health Department
evaluated the recent situation in Germany and re-
viewed the arguments for and against prophylaxis
of ophthalmia neonatorum in order to establish a
recommendation for the standard of care in Ger-
many. The arguments will be discussed here.
TABLE 3. Prophylaxis of ophthalmia neonatorum at
German university hospitals: summary of an inquiry
in January 1992 [response rate 79% (22/28)]
Deliveries/year
Number 31,700
Range 500-2,400/hospital
Observation period
(years)
Mean 5.5
Range I-I 3
Any prophylaxis 16/22 (73%)
I% Silver nitrate 12
I% Silver nitrate
occasionally
I% Silver nitrate on
request
Gentamicin
Gentamicin on request
Prophylaxis
"Controls"
0-10% Unspecific reactions,
occasionally S. aureus, O. I% C.
trachomatis, no reported
gonococcal conjunctivitis
0-5% S. aureus, 2 cases of
gonococcal conjunctivitis, some C.
trachomatis, others
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TABLE 4. Causes of ophthalmia neonatorum in the
United States
Source
Approximate Time of
frequency onset
(%) (days)
Chemical conjunctivitis 7 6-24 hours
Chlamydia trachomatis 3-13 5-14
Escherichia coli 5-9 5-21
Haemophilus spp. 5 5-21
Herpes simplex virus Rare 2-14
Neisseria gonorrhoeae 3 2-5
Staphylococcus aureus 5-30 5-21
Streptococcus viridans 4-16 5-21
For data, see Dinsmoor4.
The incidence of N. gonorrhoeae in pregnant
women in Germany is estimated to be as low as
0.1%, or approximately 700cases/year. On the
other hand, neonatal gonococcal conjunctivitis is a
severe, potentially blinding disease, that can be
prevented only if early diagnosis and adequate ther-
apy is available. 2’4’ 12 The abandonment of prophy-
laxis would without doubt lead to an increase of
ophthalmia neonatorum and its sequela, as this in-
quiry has shown (Tables 2 and 3).
Prophylaxis against gonococcal conjunctivitis
could be terminated if a sufficient, cost-effective
screening system for pregnant women (until term)
were available. However, there is no such system.
Selective application of diagnostic procedures is not
an alternative or solution, since gonoccoccal coloni-
zation in pregnancy is usually asymptomatic, the
definition of certain risk groups is almost impossi-
ble,
16 and furthermore such testing imposes an
unacceptable stigma. In addition, selective screen-
ing does not solve the problem of neonatal gonococ-
cal disease for those who are not examined.
Routine prophylaxis involves expenses in drugs,
organization, and personnel. However, these ef-
forts can be kept low and safety can be maintained
by the use of standardized, commercially available
disposable applicators.
All prophylactic procedures cause corneal irrita-
tion (Table 2) and also pain and discomfort. 7’8
However, there is no well-documented case of per-
manent or severe damage following adequate silver
nitrate application,
t9-21 Psychological aspects have
been considered by several authors, but there is also
no evidence that the degree of "eye openness" of the
newborn significantly affects the attention of the
mother immediately postpartum. The infant has
other behaviors and attributes such as cry, body
texture, movement, odor, and nursing behavior
that facilitate bonding. 22’23
Like many preventive methods, neonatal ocular
prophylaxis does not provide complete protection,
as was seen in the inquiry. This holds true for both
gonococcal conjunctivitis and other bacterial infec-
tions (Table 4), especially chlamydial disease. 24’25
However, the antimicrobial activity of silver ni-
trate covers a broad spectrum of causative agents
regardless of bacterial resistance and without the
other inherent characteristic limitations of antibiot-
ics. 4’9’12’15’18’22’24-27 The exception, C. trachom-
atis, should be of no relevance in the future, since
the German Society of Gynecology and Obstetrics
and the German Society of Perinatal Medicine de-
cided in 1992 to recommend routine screening and
therapy for chlamydial infection as a standard of
care in pregnancy.
28 In brief, the guidelines em-
phasize diagnosis as early as possible in pregnancy
by a direct test and treatment by erythromycin eth-
ylsuccinate 500 mg q.i.d, for 10 days after the 14th
gestational week; partner therapy is mandatory;
Cred6’s prophylaxis with 1% silver nitrate is also
recommended by the guidelines, since eye infec-
tions of other etiologies may still occur, and no
well-studied alternative exists.
The enforcement of Cred6’s prophylaxis in Ger-
many by law was discontinued in 1986. A restora-
tion of the old status is not desirable, since contro-
versial human rights and legal aspects are of
increasing importance. On the other hand, negli-
gence and/or abolition of routine prophylaxis that
result in damage to the newborn could probably
create another legal issue, the charge of having
neglected the current standard of care. This state-
ment accords with the results of this and Viehweg’s
inquiries and is supported as well by the literature
and by several national and international authori-
10,11,14 ties, e.g., the World Health Organization,
the Centers for Disease Control,
3 and a committee
of the German Federal Health Department. In
Germany it was also supported by at least 80% of
ophthalmologists consulted at university hospitals
(A.A. Bialasiewicz, personal communication).
Evaluation of the arguments and the literature
and the results of this inquiry appear to warrant the
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following conclusions for Germany, as drawn by
the Federal Health Department: gonococcal infec-
tion in pregnancy is a rare disease; however, the
identification and treatment of infected mothers can
not be counted on. 12’16 Therapy of the infected
infant appears to involve an unjustifiable risk.
Thus neonatal ocular prophylaxis against gonococ-
cal and other infections still appears to represent the
standard of care 1’13 and is used in the majority of
German hospitals questioned. Silver nitrate 1%
aqueous solution is considered a necessary prophy-
lactic measure, safe if properly adminis-
tered. 4’12’17’19’21’27 A new law is not warranted in
Germany for several reasons. The routine adminis-
tration of such antibiotics as penicillins, aminogly-
cosides, erythromycin, or tetracyclines cannot be
recommended as an alternative since serious unto-
ward reactions (due to poor stability and applicabil-
ity of the drug, a limited bacteriological spectrum,
selection of resistant strains, and possible allerge-
nicity for the newborn) must be taken into ac-
count. 9’15’18’25’26 The data on their efficacy are
also not superior or convincing enough to justify
their routine use in prevention of bacterial oph-
thalmia neonatorum, particularly if chlamydial in-
25,26 fection is detected and treated in pregnancy.
However, major efforts should be directed toward
conducting scientific studies on the replacement of
silver nitrate by alternative antiseptic substances
(e.g., octenidin or biguanides) in the future.
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